We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Critical Pharmaceuticals Receives Notice of Allowance from USPTO

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Critical Pharmaceuticals Receives Notice of Allowance from USPTO"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Critical Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application directed towards the Company's CP024 Intranasal Growth Hormone and CP046 Intranasal Teriparatide (parathyroid hormone 1-34) products formulated using it's proprietary CriticalSorb™ drug delivery technology.

The patent application allowed by the USPTO (application number 13/063,411) relates to pharmaceutical compositions of growth hormone or parathyroid hormone and the CriticalSorb™ absorption enhancer in a form suitable for administration to the nasal, buccal and / or respiratory tract.

Similar patent protection has already been obtained in Russia, Singapore and New Zealand with pending patents in other major territories including Europe and Japan. Together the market for growth hormone and parathyroid hormone products is in excess of $4bn per annum with strong interest in alternatives to the current daily injectable products.

Professor Lisbeth Illum, co-inventor of the CriticalSorb™ technology and an internationally recognized expert in drug delivery, said "The CriticalSorb™ formulation technology covered by this allowed application has been shown to have exceptional utility for the delivery of poorly absorbed biological and small molecule drugs in both preclinical and clinical studies. CriticalSorb™ has the potential to enable intranasal dosing of a wide-range of therapeutics and provide an attractive alternative to frequent injection that are strongly disliked by patients."

Dr Gareth King, CEO Critical Pharmaceuticals commented "The allowance of a US patent further strengthens the data package on our CP024 nasal growth hormone product that has demonstrated strong biological activity in Phase I clinical trials. It will provide important protection to future license partners for the continued development and commercialization of CP024 and CP046 intranasal teriparatide products."

The allowed applications are part of Critical Pharmaceuticals broader capability and intellectual property in advanced drug delivery and formulation technology for challenging molecules such as peptide, protein and antibody drugs.

La Marie Business Intelligence recently estimated this market to be worth in excess of $140bn and growing at +12% a year. Potter Clarkson LLP, a leading European firm of patent and trademark attorneys, advises the company on intellectual property matters.

The CriticalSorb™ technology was developed by Critical Pharmaceuticals scientists in Nottingham, UK. Dr Faron Jordan, co-inventor of the CriticalSorb™ technology and Head of Preclinical and Clinical Project Management at Critical Pharmaceuticals, said “The CriticalSorb™ technology has rapidly progressed from the lab to clinical proof of concept. I’m extremely pleased with the allowance of the US patent application and look forward to progressing additional Critical Pharmaceuticals products and partner programs into the clinic and into the hands of patients who prefer nasal administration over injection."